Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma

BACKGROUND: Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine the recommended phase 2 dose (RP2D) of DMF and evaluate its safety and...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neurooncol Adv
मुख्य लेखकों: Shafer, Danielle, Tombes, Mary Beth, Shrader, Ellen, Ryan, Alison, Bandyopadhyay, Dipankar, Dent, Paul, Malkin, Mark
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2020
विषय:
Clinical Investigations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212848/
https://ncbi.nlm.nih.gov/pubmed/32642720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz052
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन